

Application No.: 10/623076

Docket No.: BPI-189

In the specification:

Please replace the second paragraph beginning at page 1, line 17 with the following paragraph:

This application is related to U.S. utility applications 10/622932 (Attorney Docket No. BPI-187) entitled "Treatment of TNF $\alpha$ -Related Disorders Using TNF $\alpha$  Inhibitors," (Attorney Docket No. BPI-188) 10/623039 entitled "Treatment of Spondyloarthropathies Using TNF $\alpha$  Inhibitors," (Attorney Docket No. BPI-189) entitled "Treatment of Pulmonary Disorders Using TNF $\alpha$  Inhibitors," (Attorney Docket No. BPI-190) 10/623065 entitled "Treatment of Coronary Disorders Using TNF $\alpha$  Inhibitors," (Attorney Docket No. BPI-191) 10/622928 entitled "Treatment of Metabolic Disorders Using TNF $\alpha$  Inhibitors," (Attorney Docket No. BPI-192) 10/623075 entitled "Treatment of Anemia Using TNF $\alpha$  Inhibitors," (Attorney Docket No. BPI-193) 10/623035 entitled "Treatment of Pain Using TNF $\alpha$  Inhibitors," (Attorney Docket No. BPI-194) 10/622683 entitled "Treatment of Hepatic Disorders Using TNF $\alpha$  Inhibitors," (Attorney Docket No. BPI-195) 10/622205 entitled "Treatment of Skin and Nail Disorders Using TNF $\alpha$  Inhibitors," (Attorney Docket No. BPI-196) 10/622210 entitled "Treatment of Vasculitides Using TNF $\alpha$  Inhibitors," (Attorney Docket No. BPI-197) 10/623318 entitled "Treatment of TNF $\alpha$ -Related Disorders Using TNF $\alpha$  Inhibitors," and PCT application PCT/US2003/022566 (Attorney Docket No. BPI-187PG) entitled "Treatment of TNF $\alpha$ -Related Disorders," all of which are filed on even date herewith. The entire contents of each of these patents and patent applications are hereby incorporated herein by reference.